Published in PLoS One on April 22, 2014
Cirrhotic Multiorgan Syndrome. Dig Dis Sci (2015) 0.82
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med (1999) 18.50
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens (2003) 11.32
Tutorial in biostatistics: competing risks and multi-state models. Stat Med (2007) 10.61
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol (2010) 4.55
Global challenges in liver disease. Hepatology (2006) 4.55
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol (2000) 3.43
Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology (2009) 3.20
Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology (2010) 2.87
Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol (2003) 2.46
Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol (2010) 2.37
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol (2012) 2.30
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol (2012) 1.62
Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol (2009) 1.38
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol (2003) 1.34
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest (2009) 1.32
Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology (1989) 1.20
Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut (2010) 1.15
The relationship of cirrhosis of the liver to hypertension: a study of 504 cases of cirrhosis of the liver. Am J Med Sci (1955) 1.14
Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology (2009) 1.02
Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut (2006) 0.98
Reduction of hypertension after liver disease. Arch Intern Med (1962) 0.88
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol (2010) 0.87
Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. World J Gastroenterol (2009) 0.77